March 31 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON - AT DAY 15 OF COVID-19 TRIAL THERE WAS 0% MORTALITY IN 20 MG DOSE IFENPRODIL TREATMENT ARM VERSUS 3.3% MORTALITY RATE IN UNTREATED CONTROL ARM
* ALGERNON PHARMACEUTICALS INC - BASED ON INITIAL DATA REVIEW, NO SIGNIFICANT CHANGES WERE OBSERVED IN 40 MG DOSE GROUP
* ALGERNON - OF PATIENTS WITH LOW BLOOD OXYGEN LEVEL, 100% IN 20 MG DOSE TREATMENT ARM RETURNED TO NORMAL LEVELS OF O2 AT DAY 4 VERSUS DAY 9 IN UNTREATED ARM